

Subject Index

a

- A 77 1726 *see* leflunomide
- A 95 0277 *see* leflunomide
- A β *see* amyloid A β
- A β 1-42, Alzheimer's disease marker
 - sensitivity and specificity 262
- aberration, chromosomal 225
- absorption, distribution, metabolism, excretion studies 162
- abundance changes, MCF-7 cells plasma membrane proteins 253
- abundance ratio, MD-LC 93
- abuse, alcohol 300
- accelerating voltage, MALDI-TOF MS 283
- acceptor beads, anti-GST 169
- acetylcholinesterase inhibitors, Alzheimer's disease treatment approaches 260
- acid-labile isotope-coded extractants (ALICE) 74
- acridin orange, DNA stain 165
- actin
 - BIAcore chip 196
 - brain proteins 284
- actin (γ 1), DIGE molecular markers 47
- actin-binding protein, cortactin 213
- activity testing, *in vitro* 190
- acute allograft rejection, markers 307–307
- acyl chlorides synthesis, thionyl chloride method 192
- acyl cyanides
 - SMART target identification 192
 - structure–activity relationship with A 77 1726 201
- AD *see* Alzheimer's disease
- ADME studies 162
- administrative networking, realization in brain proteome projects 10–16
- administrative optimization, proteomics networks 3–16
- AF *see* affinity chromatography
- affinity chromatography (AF), MD-LC
 - selective filters 90, 94
 - multicolumn 107
 - SMART target identification 190–191
- affinity matrix, albumin and IgG removal 106
- aging 259
- albumin, high-abundance proteins 105–106
- alcohol abuse, sustained 300
- algorithms
 - Mascot 67
 - Sequest 67
- ALICE *see* acid-labile isotope-coded extractants
- alkylating agents, plasma membrane 245
- alkylating reagents, biotinylated 245
- alleles, ApoE gene 266
- allocation, resources 323, 326
- allograft rejection, acute 307–307
- alpha tropomyosin, differential abundance in mitoxantrone resistant MCF-7 cells 252
- AlphaScreen
 - comparison with other biomolecular interaction analysis methods 170
 - pharmaceutical screening tool 167–169
 - schematic representation 168
- Alzheimer's disease
 - biomarkers 267–271
 - brain proteins with deranged levels and modifications 284–294
 - diagnosis 259, 261–263, 280
 - discrimination from non-Alzheimer dementia types 265, 268–269
 - HBPP2 12
 - neurochemical markers 260–272
 - phosphorylated tau protein biomarker 265–266
 - proteomics 279–294
 - pTau181 biomarker 265
 - treatment approaches 259–260

- American Society for Tests and Measures (ASTM), mass spectrometry data format 26–27
 - amino acid leucine, deuterated 71
 - amino acids
 - cell culture 71–72
 - isotope-labeled 249
 - amyloid A β
 - alzheimer's disease biomarker 119
 - quantitative immunoblot 262
 - quantitative SDS-PAGE 262
 - amyloid A β peptides, release 261
 - amyloid plaques
 - enriched proteins 293–294
 - protein detection 284
 - β -amyloid deposits, Alzheimer's disease neuropathological markers 260
 - β -amyloid precursor protein *see* β -APP
 - analysis of variance (ANOVA), DIGE data 52
 - analysis time, MD-LC advantages 92
 - analysis tools, proteins 21–23
 - analytical chemistry, peptide research 121
 - analytical methods, peptides 120–121
 - animal models, heart disease 301–302
 - anisotropy, fluorescence *see* fluorescence polarization
 - annexin A2/A4, DIGE molecular markers 47
 - ANOVA *see* analysis of variance
 - anti-GST acceptor beads 169
 - anti-inflammatory therapy, new therapeutic target from phosphoproteome analysis 218–219
 - anti-phosphotyrosine, phosphoproteome analysis 214
 - antibodies
 - humanized 150
 - immobilization in biochips 141
 - antibody arrays, micro format immunoassay 149
 - antibody microarrays
 - performance 139
 - schematic representation 144
 - antibody repertoire, profiling 146
 - anticipated business impact 322
 - antigens, cardiac 306
 - antioxidant proteins, levels in Alzheimer's disease brain samples 293
 - antitumor therapy, DPPiV inhibitors 127
 - apical plasma membrane enrichment, colloidal silica method 246
 - ApoE, genotype 266
 - apolipoprotein E *see* ApoE
 - apoptosis
 - activator 253
 - Alzheimer's disease 292–294
 - caspase-dependent 254
 - inhibition 242
 - protection 308
 - β -APP, metabolism and impact on Alzheimer's disease diagnosis 261–263
 - Arabidopsis thaliana*, high-throughput subcloning 142–143
 - Arava *see* leflunomide
 - archaea, proteome analysis 22
 - archive, UniParc 21
 - arsinh, graph (for data normalization) 49
 - assay formats, biomolecular interaction analysis 160
 - ASTM *see* American Society for Tests and Measures
 - atherosclerotic vessels, proteomics 307
 - ATP
 - cell death 202
 - production 302
 - ATP-dependent membrane pumps, drug resistance protein contributors 242
 - ATPases, enriched in amyloid plaques 294
 - atrial isoforms, myosin light chains (MLC) 306
 - autoantibodies, cardiac-specific 300
 - autoantigens, tumor-specific 226
 - autoimmune diseases
 - antibody–antigen interactions 145–146
 - inhibition of cell proliferation 202
 - rheumatoid arthritis (RA) *see* rheumatoid arthritis
 - systemic lupus erythematosus (SLE) 146, 202
 - autoimmune repertoire, humoral 145
 - autoradiography
 - 2D phosphoproteomics 219
 - anti-phosphotyrosine 214
 - phosphoprotein visualization 209
 - phosphorylated human platelet proteins 212
- b**
- bacteria, proteome analysis 22
 - basolateral plasma membrane enrichment, colloidal silica method 246
 - BCR-ABL protein 171
 - BCRP
 - drug resistance protein contributors 242
 - up-regulated in plasma membrane 254
 - BDNF, neurotrophin 39
 - bead-based assays, *in vitro* characterization of protein interactions 161
 - beads, immobilized streptavidin carrying 245

- Bernard-Soulier syndrome, genetic bleeding disorders 212
- $\beta 1$, transforming growth factor 267
- Betaseron *see* interferon- β
- BIA *see* biomolecular interaction analysis
- BIAcore analysis
 - identification of enzymic binding partners 189
 - SMART target identification 191–192
- BIAcore chip, binding diagram 197
- BIND
 - protein–protein interaction database 27
 - public domain database 24
- binding analysis, PKA regulatory subunit 162–163
- binding diagram, BIAcore chip 197
- bioactive peptides 120
- biochemistry, peptides 116
- biochips
 - German Human Brain Proteome Project 11
 - protein and antibody immobilization 141
 - signal amplification 142
- bioinformatic data analysis software, Spectormania 122
- bioinformatics tools 20
- biological confounding factors, cerebrospinal fluid analysis 270
- biological interaction, MD-LC protein separation 95
- biological mass spectrometry 57–81
 - first application 57
 - instrumentation 62–65
 - ion formation 62
- biological systems, coding of meaning 174
- biomarker analysis, multiparametric 223
- biomarkers
 - Alzheimer’s disease 267–267
 - definition 118, 125
 - definitions and conceptual model 228–229
 - discovery 223–235
 - evaluation 7–8
 - gastric cancer 228
 - molecular risk 228
 - multimodal approach 225
 - nasopharyngeal carcinoma 228
 - peptide-based 119
 - peptides 118
 - rational approaches for renal cell carcinoma (RCC) 225–226
 - renal cell carcinoma 223–235
- Biomarkers Definitions Working Group 228
- biomolecular interaction analysis (BIA) 159
 - assay formats 160
 - method comparison 170
- biopsies
 - endomyocardial specimens 307
 - renal cell carcinoma 229–233
 - tumor 226
- biosensors, surface plasma resonance (SPR) 161–163
- biosynthesis, pyrimidine 195
- biotechnology companies, concentration in Switzerland 7
- biotinylated alkylating reagents, plasma membrane protein enrichment 245
- biotinylated molecules, AlphaScreen assay 167, 169
- biotinylating reagent, membrane-impermeable 74
- bleeding disorders 212
- blood, peptide research 118
- blood assays, early and differential diagnosis of dementia 259–272
- blood platelets *see* platelets
- blood test, ELISA-based 307
- blood vessels, LCM samples protein map 311
- blue native (BN) electrophoresis, two-dimensional 304
- BMBF *see* German Federal Ministry of Education and Research
- BN *see* blue native
- BNP *see* human B-type natriuretic peptide
- body fluids
 - clinical neuroproteomics 259–272
 - peptide identification 123
- bone marrow, megakaryocytes 210
- “bottleneck” in proteome analysis, sample clean-up 104–109
- bottom-up proteomics, MD-LC 99
- bovine dilated cardiomyopathy (DCM) 301
- brain, 2D-protein map 289
- Brain natriuretic peptide (BNP), congestive heart failure biomarker 119
- brain parenchyma, biochemical composition changes 260
- brain proteins
 - sample preparation 281
 - with deranged levels and modifications in Alzheimer’s disease and/or DS 284–294
- Brain Proteome Project of the Human Proteome Organisation *see* HUPO Brain Proteome Project
- brain proteome projects, realization of administrative networking 10–16
- brain samples, postmortem 280
- breast cancer cell line, MCF-7 120

- breast cancer cells, human 241–254
 breast cancer resistance protein *see* BCRP
 browser, Integr8 22
 business impact, anticipated 322
- c**
- C-peptide, diabetes biomarker 119
¹³C₆-arginine, stable isotope labeling 71
¹³C₆-lysine, stable isotope labeling 71
 CA-IEF *see* carrier ampholyte isoelectric focusing
Caenorhabditis elegans
 – ¹⁵N labeling 71
 – high-throughput subcloning 142–143
 CAIX *see* carboanhydrase 9
 calcitonin, peptide-based pharmaceutical 117
 calibration, protein expression data 48–50
 calorimetric methods, *in vitro* characterization of protein interactions 161
 cAMP-dependent protein kinase *see* PKA
 cancer cells, human breast 241–254
 candidate markers 234
 capital expenditure 329
 carboanhydrase 9 (CAIX), renal cell carcinoma (RCC) biomarkers 229
 carbohydrate microarrays, schematic representation 144
 carbomethoxypropionylcyanide (CMPC) *see* CMPC
 carboxymethylated sensor chip CM5, surface matrix activation 191
 carboxypeptidase E (Cpe) 127–129
 cardiac antigens, proteomic characterization 306
 cardiac fibroblasts, embryonic 218
 cardiac hypertrophy, animal models 301
 cardiac myocytes
 – cultured 305–306
 – LCM samples protein map 311
 – neonatal 305
 cardiac proteins, differential expression 300–301
 cardiac proteomics 299–312
 cardiac-specific antigens 306
 cardiac-specific autoantibodies, dilated cardiomyopathy (DCM) contributory factors 300
 cardiac transplantation, acute allograft rejection 307
 cardiomyopathy, dilated 300–301
 cariac allograft vasculopathy (CAV) 308
 carrier ampholyte isoelectric focusing (CA-IEF), in 2-DE 34
 caspase-dependent apoptosis 254
 cathepsin, enriched in amyloid plaques 294
 CAV *see* cariac allograft vasculopathy
 CCD camera, multi-epitope ligand kartographie (MELK) robotic systems 177
 CD26, lymphocyte glycoprotein 126
 cDNA expression libraries 143
 – antibody repertoire profiling 146
 cell and tissue microarrays, schematic representation 144
 cell class, GeneOntology (GO) 40
 cell culture
 – amino acids 71–72
 – cardiac myocytes 305–306
 cell death, ATP and NAD concentrations 202
 cell lines
 – breast cancer 120
 – human breast cancer 243
 – neuroblastoma SY5Y 39
 – organelle proteomics 243–244
 – renal cell carcinoma 229–233
 cell proteome, syntactic and semantic structures 175
 cell states, functional 178–179
 cell surface membrane, experimental analysis of molecular networks 181
 cells
 – human breast cancer 241–254
 – immortalized 310
 – involved in immune response and inflammatory processes 193
 – morphologically intact 173–182
 – muscle 178
 – SMART target identification 190
 cellular protein patterns, comparison with protein profiles 178
 central nervous system (CNS) 260
 – diseases 267
 cerebrospinal fluid (CSF)
 – combination of 3 biomarkers 270
 – increased total tau in Alzheimer's disease 264–265
 – phosphorylated tau protein 265–266
 – protein levels 284
 – quantitative A β SDS/PAGE/immunoblot 262
 cerebrospinal fluid analysis
 – central nervous system diseases 267
 – combined parameter analysis 267–270
 – preanalytical and biological confounding factors 270
 – early and differential diagnosis of dementia 259–272
 cerebrospinal fluid-flow rate-related protein diffusion 272

- cerebrospinal fluid/serum analysis 272
- cGK activation, platelets 216
- cGMP-dependent protein kinase *see* PKG
- chains, tubulin 284
- chaperonins, deranged levels in Alzheimer's disease brains 293
- chaperons, enriched in amyloid plaques 294
- charge, MD-LC protein separation 95
- chemical labeling
- biological mass spectrometry 73–77
 - isotope 73–74
 - mapping of protein complexes 79
 - schematic representation 68
- chemotherapeutic agents, drug resistance 242
- chip content 142–144
- cholecystokinin, discovery 115
- cholesterol transport, ApoE 266
- chromatographic platform configuration, multicolumn 108
- chromatography
- ion exchange *see* ion exchange chromatography
 - MD-LC sample clean-up 94
- chromosomal aberration detection 225
- chromosome 17, tau protein 263
- chromosome 19, ApoE gene 266
- chromosome 21, β -APP 261
- chromosome 3p deletion, renal cell carcinoma (RCC) 224
- chronic myelogenous leukemia (CML), novel drug Gleevec 171
- chronic neuroinflammatory diseases (CID), discrimination from Alzheimer's disease 269
- CID *see* chronic neuroinflammatory diseases
- clathrin, enriched in amyloid plaques 294
- clinical neuroproteomics, human body fluids 259–272
- clinical peptidomics 118–120
- clinical research, DIGE 33–52
- clinical success rate, drug development 173
- clinical trials, drug development 124
- CluSTr, proteome analysis project 22
- CM5, carboxymethylated sensor chip 191, 196
- CML *see* chronic myelogenous leukemia
- CMP *see* combinatorial molecular pattern
- CMPC
- medicinal chemistry 203
 - molecular structure 200
 - novel rheumatoid arthritis (RA) drug 199
- CNPase, reduced level in Alzheimer's disease 291
- CNS *see* central nervous system
- coagulation, influence on peptide content 119
- coding principle, proteins 174
- cofilin, LPS-stimulatory effect 194
- collision-induced dissociation (CID), biological mass spectrometry 62–64
- colloidal Coomassie, 2-DE staining methods 35
- colloidal silica method, apical and basolateral plasma membrane enrichment 246
- column miniaturization, MD-LC 97
- combinatorial molecular pattern (CMP) 179–181
- commercial risks 328, 330
- commercialization, life science 5–6
- comparative densitometry, digitized 2D gel maps 249
- comparative genomic hybridization, chromosomal aberration detection 225
- complex protein mixtures
- analysis 33
 - separation 90
- confounding factors, cerebrospinal fluid analysis 270
- connecting peptide, diabetes biomarker 119
- Coomassie, colloidal 35
- Coomassie blue, 2D electrophoresis staining 289
- Coomassie dyes, blue native (BN) electrophoresis 304
- coronin tau, enriched in amyloid plaques 294
- cortactin, differential phosphoproteome analysis 213–213
- cortex, parietal 290
- Coulomb explosion, electrospray ionization 61
- covalent protein derivatization, DIGE detection method 36
- Cpe *see* carboxypeptidase E
- creatine kinase, oxidative stress 293
- creativity 335
- crossreactivity, antibodies 145
- CSF *see* cerebrospinal fluid
- culture conditions, SMART target identification 190
- cultured cardiac myocytes, proteomics 305–306
- customer relations 324
- cutting edge, technological innovation 323
- Cy5/Cy3 spot volumes, minimal CyDye gel 48
- α -cyano-4-hydroxycinnamic acid (HCCA), “hot” MALDI matrix 58–59

- cyler robots, imaging 177–179
 2', 3'-cyclic nucleotide-3'-phosphodiesterase
 see CNPase
 cyclophilin B, differential abundance in
 mitoxantrone resistant MCF-7 cells 252
 cyclosporine, peptide-based pharmaceutical
 117
 CyDye DIGE minimal fluors
 – general procedure 38–39
 – labeling chemistry 39
 – minimal labeling 38–44
 CyDye DIGE saturation fluors
 – general procedure 44–45
 – labeling chemistry 44
 – molecular tumor marker analysis 45–47
 – saturation labeling 44–47
 CyDye gel (minimal), Cy5/Cy3 spot volumes
 48
 cystatin C, renal failure biomarker 119
 cytokeratin, differential abundance in
 mitoxantrone resistant MCF-7 cells 252
 cytoskeletal proteins, enriched in amyloid
 plaques 294
 cytosol, isolation 244
 cytosolic brain proteins, sample preparation
 281
- d**
- data, storage and retrieval 23–24
 data analysis software
 – bioinformatic 122
 – MicroCal Origin 165
 databases
 – 2-D gel protein 300
 – heart proteins 300
 – HEART-2DPAGE 300
 – HP-2DPAGE 300
 – HSC-2DPAGE 300
 – MEROPS 125
 – PRIDE 15
 – protein families, domains and functional
 sites 22
 – protein–protein interactions 27
 – public domain 24
 – RAT HEART-2DPAGE 300
 – Reactome 23
 – UniProt 21
 Data Collection Center (DCC), HUPO BPP
 13, 15–16
 data generation, high-quality 100
 data handling software, ProteinScape 15
 data interchange formats
 – mass spectrometry 25–27
 – protein–protein interactions 27
 – data mining, disease-oriented proteome
 analysis 9–10
 – data normalization, function graphs 49
 – data object model, PSI-OM 25
 – data sets, toponome 180
 DCC *see* Data Collection Center
 DCM *see* dilated cardiomyopathy
 2D-DIGE, sample preparation workflow 41
 2DE
 – Alzheimer's disease proteomics 282
 – first development 34
 – image analysis software 35
 – protein detection 36–52
 – representative map of kidney epithelium
 233
 – representative map of renal cell carcinoma
 (RCC) biopsy 233
 – reproducibility variations 35
 – schematic representation 34
 – staining methods 35
 – tumor-specific autoantigen identification
 226
 deciphering apparatus, molecular networks
 182
 DeCyder, DIGE image analysis software
 37, 48
 2DE-gels, SY5Y–TrkA(B) cell lysate 40
 degradation processes, mRNA 122
 2D electrophoresis *see* 2DE
 dementia
 – cerebrospinal fluid and blood assay
 diagnosis 259–272
 – genetic cause 280
 – major cause 260
 – non-Alzheimer types 265, 268
 dendrimers, protein biochips surface coating
 139–140
 densitometry
 – comparative 249
 – differential nuclear protein abundances
 251
 depolarization, fluorescence polarization 166
 deposition, proteomic data 19–21
 deranged protein levels, Alzheimer's disease
 and/or DS 284–294
 derivatization (covalent), proteins 36
 detection method, DIGE 36
 deuterated amino acid leucine ($^2\text{H}_3\text{-Leu}$),
 stable isotope labeling 71
 development costs, drugs 124, 173
 development tools, innovation process
 concept 321
 2D gel array, MCF-7 cell nuclear proteins 248
 2D gel maps, digitized 249

- 2D gels, underrepresented protein classes 294
- DHB *see* 2,5-dihydrobenzoic acid
- DHODH
- binding diagram 197
 - inhibition 189
 - key enzyme in pyrimidine biosynthesis 195
 - leflunomide-binding proteins 192
- diabetes mellitus, DPPIV inhibitors 126
- diagnosis, *intra vitam* 271
- diagnostic marker, premortem 279
- diagnostics, peptide-based 119
- difference gel electrophoresis *see* DIGE
- differential phosphoproteome analysis 209–219
- future developments 219
- differential diagnosis, dementia 259–272
- differential display peptidomics, applications 124–128
- differential expression
- annexin IV 234
 - cardiac proteins 300–301
- differential gene expression, monitoring 137
- differential nuclear protein abundances, mitoxantrone resistant and susceptible cells 251–252
- differentially expressed proteins, detection 50–51
- differentially expressed renal cell carcinoma proteins, validation 234
- DIGE
- 2-DE staining methods 35
 - applications 52
 - cerebrospinal fluid analysis 271
 - clinical research 33–52
 - CyDye minimal fluors 38–44
 - CyDye saturation fluors 44–47
 - development 36
 - Ettan® 37
 - image analysis software 37
 - novel search Alzheimer’s disease biomarker techniques 270–271
 - protein detection 36–52
 - proteome analysis 47–52
 - saturation 35
- digestion, trypsin 102
- “digestion-free” strategy, MD-LC 99
- digestion strategy, MD-LC/MS methods 98–100
- digitized 2D gel maps, comparative densitometry 249
- dihydro-orotate dehydrogenase *see* DHODH
- 2,5-dihydrobenzoic acid (DHB), “cool” MALDI matrix 58–59
- dihydropyrimidinase-related protein *see* DRP-2
- dihydropyrimidinase-related proteins-2 and -3, brain 284
- dilated cardiomyopathy (DCM) 300–301
- bovine 301
 - patients’ humoral autoimmune repertoire 145
- 1-dimensional polyacrylamide gel electrophoresis *see* 1D-PAGE
- 2-dimensional electrophoresis *see* 2DE
- 2-dimensional polyacrylamide gel electrophoresis *see* 2D-PAGE
- dimeric–tetrameric interconversion, M2-PK 198–199
- DIP
- protein–protein interaction database 27
 - public domain database 24
- dipeptides, definition 116
- direct assay format, AlphaScreen assay 169
- direct injection
- biological samples in MD-LC 107
 - untreated biological samples 106
- direct metabolic effects, A 77 1726 200
- direct sample injection, solid phase extraction (SPE) 106
- discovery-oriented proteomics 138
- disease-oriented proteome analysis 9
- disease-related information, urinary proteome 227
- 2D-LC system, fully automated 109
- DNA expression libraries 143
- antibody repertoire profiling 146
- DNA microarray technology, high density 137
- DNA oxidation, neurodegenerative pathologies 293
- DNA repair protein RAD51B, interactions with histones 147
- dominant cell type, heart tissue 311
- donor beads, streptavidin-coated 167
- dose-response assay, fluorescence polarization 166
- double inhibition, proteins 181
- down syndrome (DS)
- biomarker evaluation 7
 - brain proteins with deranged levels 285–289
 - genetic cause of dementia 280
 - proteomics 280
- doxorubicin
- drug resistance 243
 - molecular structure 244
- 1D-PAGE, protein identification 65–66

- 2D-PAGE
 - German Human Brain Proteome Project 11
 - phosphoproteome analysis 209
 - protein identification 65–66
 - 2D phosphoproteomics, autoradiography 219
 - DPPIV
 - inhibitors 126–127
 - peptide-processing peptidase 126
 - 2D protein databases, heart 300
 - 2D-protein map
 - human brain 289
 - parietal cortex 290
 - Drosophila* hemolymph, MALDI–TOF–MS spectra 122
 - DRP-2 286
 - oxidative modification 291
 - drug design, isothermal titration calorimetry (ITC) 163–165
 - drug development
 - administrative optimization of proteomics networks 3–16
 - clinical trials 124
 - costs 173, 187
 - gain of functional information 182
 - molecular networks in morphologically intact cells and tissue 173–182
 - peptidomics 124–127
 - proteomics networks 9–10
 - drug discovery
 - biological mass spectrometry 57–81
 - target identification 125
 - drug research
 - peptides 114–120
 - peptidomics technologies and applications 113–130
 - proteomics applications 187–312
 - drug resistance
 - chemotherapeutic agents 242
 - clinical problem and proteomics response 242–243
 - organelle proteomics 241–254
 - to mitoxantrone 252–254
 - drug target identification
 - materials and methods 190–193
 - SMART 187–203
 - “druggable” targets 188
 - drug–protein interactions, plasma membrane 245
 - drugs
 - average development costs 124
 - peptides 117–118
 - drug–therapeutic target interactions, thermodynamic characterization 163
 - DS *see* down syndrome
 - durante vitam* diagnosis, Alzheimer’s disease 259
 - dye maleimide group, CyDye DIGE saturation fluors 44
 - dynamic range
 - MD-LC 92
 - proteome 91
 - dynamin 1, enriched in amyloid plaques 294
 - dynein, enriched in amyloid plaques 294
- e**
- E. coli see* *Escherichia coli*
 - early diagnosis, dementia 259–272
 - EBI *see* European Bioinformatics Institute
 - EBV, nasopharyngeal carcinoma biomarker 228
 - EF-1-beta, differential abundance in mitoxantrone resistant MCF-7 cells 252
 - efficacy markers, evaluation 7–8
 - EHSA *see* environmental, health and safety administration
 - electric charge, MD-LC protein separation 95
 - electric field, MD-LC sample clean-up 94
 - electrophoresis
 - blue native (BN) 304
 - SMART target identification 191
 - two-dimensional 282
 - electrospray ionization (ESI) 58, 60–62
 - peptide ionization techniques 121
 - β -elimination, label cleavage 73
 - ELISA 114, 120
 - blood test 307
 - in comparison to multiplex technology 271
 - in comparison to protein biochips 146
 - embryonic cardiac fibroblasts, murine 218
 - EmCa *see* endometrial cancer
 - endogenous peptides, top-down identification 123–124
 - endometrial cancer (EmCa) tissue, chemical labeling 77
 - endomyocardial biopsy specimens, proteomics 307
 - endothelial cells, isolated 308
 - energy, free 163
 - enrichment, plasma membrane proteins 245
 - Ensembl, rat proteome database 23
 - enthalpy, free 163
 - entropy 163
 - environmental, health and safety administration (EHSA) risks 328, 330
 - enzyme activities, microarrays 148
 - enzyme array 151
 - enzyme complex, glycolytic 196

enzyme inhibition assays 151
 enzyme-linked immunosorbent assays
 see ELISA
 enzymes
 – housekeeping 284
 – ubiquitin carboxyl-terminal hydrolase (UCH) 301–302
 enzymic binding partners, identification via BIAcore analysis 189
 EP *see* exploratory project
 epidermal growth factor receptor (EGFR), HeLa cells 80
 epithelial adhesion molecules, renal cell carcinoma (RCC) proteome analysis 230
 epithelial cells, ovarian surface 104
 error, statistical (Type I/II) 51
Escherichia coli, ¹⁵N labeling 70–71
 ESI *see* electrospray ionization
 ESI qTOF, schematic representation 64
 ESI/HPLC, nanoscale 65
 etoposide
 – drug resistance 243
 – molecular structure 244
 Ettan® DIGE, workflow 37
 eukaryotes, proteome analysis 22
 eukaryotic ribosome, identification of components 103
 European Bioinformatics Institute (EBI) 14–15
 – UniProt 21
 European Heads of Research Council 4
 European Union 5
 evaluation project (EvP) stage, innovation process 327–329
 EvP *see* evaluation project
 expenditure, capital 329
 experimental analysis, molecular networks of the cell surface membrane 181
 experimental design, organelle proteomics 243–252
 exploratory project (EP) stage, innovation process 329–331
 expression, differential 300–301
 expression libraries, cDNA 143
 expression vectors 150
 extracellular β -amyloid deposits, Alzheimer's disease neuropathological markers 260

f
 fast atom bombardment (FAB) 57
fat/fat mouse, peptidomics *in vivo* model 127–129
 feasibility confirmation, initial 329
 femtomole range, sample concentrations 59

fibroblasts
 – cardiac 218
 – isolated 308
 filters, selective 93–94
 fingerprint, toponome 178
 first to market 324
 fluorescein, fluorophore 165
 fluorescence, first observation 165
 fluorescence correlation spectroscopy (FCS), early diagnosis of Alzheimer's disease 272
 fluorescence polarization (FP)
 – *in vitro* characterization of protein interactions 161
 – comparison with other biomolecular interaction analysis methods 170
 – dose-response assay 166
 – high-throughput screening tool 165–167
 fluorophores 165
 formalization, network motifs as geometric objects 179–181
 formation, 3-nitrotyrosine 293
 Forte *see* human parathyroid hormone
 Fourier transform ion cyclotron resonance (FT-ICR) 124
 FP *see* fluorescence polarization
 fractionation
 – MD-LC 101
 – plasma membrane proteins 247–249
 – size-selective 107
 – strong cation exchange chromatography 101
 fragment ion spectra, nonphosphorylated and phosphorylated peptides 215
 free energy 163
 free enthalpy 163
 frontotemporal dementia (FTD), discrimination from Alzheimer's disease 265–266
 FSC *see* fluorescence correlation spectroscopy
 FTD *see* frontotemporal dementia
 FT-ICR *see* Fourier transform ion cyclotron resonance
 fully automated 2D-LC system, peptidomics screening 109
 functional cell states 178–179
 functional coding principle, proteins 174
 functional information, perspectives for drug development 182
 functional proteomics, quantitative mass spectrometry 67–69
 functional units, protein patterns 177
 functionalized sensor surface 162
 fusion competence, functional cell states 178–179

g

GAPDH
 – binding diagram 197
 – glycolytic enzyme complex 196
 – leflunomide-binding proteins 192
 gastric cancer biomarker, *Helicobacter pylori* 228
 gastrin, discovery 115
 gate, innovation process 326
 gel protein databases 300
 gene expression, differential 137
 GeneOntology (GO) cell class 40
 General Proteomics Standards (GPS), data model 14, 24–25
 genetic bleeding disorders 212
 genetic factors, dilated cardiomyopathy (DCM) contributory factors 300
 genome research network, human brain proteome project 11–14
 genomic hybridization, comparative 225
 Genotropin *see* human growth hormone
 German Federal Ministry of Education and Research (BMBF) 11
 German Human Brain Proteome Project (HBPP) 3
 – adapted workflow 12
 – initiation 11
 GFAP *see* glial fibrillary acidic protein
 Gibbs-Helmholtz equation 164
 GK activation, platelets 216
 Glanzmann thrombasthenia, genetic bleeding disorders 212
 Gleevec (Imatinib), novel drug against chronic myelogenous leukemia 171
 glial fibrillary acidic protein (GFAP) 287, 290
 global internal standard technology (GIST), stable isotope labeling 75
 glucagon
 – hormone precursor 116
 – peptide-based pharmaceutical 117
 – *see* glucagon
 glucose consumption, inhibition by A 77 1726 200
 glutamic acid, molecular structure 200
 glutaminolysis 198
 glycolytic enzyme complex 196
 GMP-dependent protein kinase *see* PKG
 GO *see* GeneOntology (GO)
 GO Slim, proteome analysis project 22
 GO/NO GO criterion, innovation process concept 327, 329
 gold-coated microarrays, surface plasma resonance (SPR) 140
 GPS *see* General Proteomics Standards

grammar, cell proteome 175
 78K GRP, differential abundance in mitoxantrone resistant MCF-7 cells 252
 guidance proteins, Alzheimer's disease proteomics 291

h

$^2\text{H}_3\text{-Leu}/^2\text{H}_{10}\text{-Leu}$, stable isotope labeling 71
 HBPP *see* (German) Human Brain Proteome Project
 HCCA *see* α -cyano-4-hydroxycinnamic acid
 heart
 – 2-D protein databases 300
 – subproteomics 302
 HEART-2DPAGE, 2-D protein databases 300
 heart disease
 – animal models 301–302
 – proteomic characterization of cardiac antigens 306
 heart failure, animal models 301
 heart proteomics 300–307
 heart tissue, dominant cell type 311
 heat shock proteins (HSP)
 – Alzheimer's disease proteomics 293
 – brain 284
 – isoelectric isoforms 301
 – mouse cardiac fibroblasts 219
 – potential A 77 1726 binding partners 202
 HEK 293 cells, transfected 270
 HeLa cell proteins, *in vivo* methylation 72
 HeLa cells, epidermal growth factor receptor (EGFR) 80
Helicobacter pylori, gastric cancer biomarker 228
 Helmholtz *see* Gibbs-Helmholtz equation
 hemostasis, protein disulfide isomerase (PDI) 214
 heterogeneous annexin IV expression, western blot analysis 234
 HGP *see* Human Genome Project
 HIC *see* hydrophobic interaction
 high density DNA microarray technology 137
 high-pressure liquid chromatography *see* HPLC
 high-quality data generation, MD-LC/MS 100
 high resolution proteomics technologies, SMART 188
 high-resolution separation, protein samples 34
 high-throughput screening
 – fluorescence polarization 165–167
 – ligand–receptor interactions 151
 – target-driven drug discovery programs 194
 high-throughput subcloning 142

- HILIC *see* hydrophilic interaction
 histological images, PanIN grades 45
 histones, interactions with DNA repair protein RAD51B 147
 HMG-1, differential abundance in mitoxantrone resistant MCF-7 cells 252
 hnRNP K, "RNA silencer" 43
 homodimer, noncovalent 214
 hormone precursors 116
 housekeeping enzymes, brain proteins 284
 HP-2DPAGE, 2-D protein databases 300
 HPLC, coupled with electrospray ionization MS 58, 61–62
 – nanoscale 65
 – peptide research 121
 HPR (Human Proteome Resource) 144
 HSC-2DPAGE, 2-D protein databases 300
 HSP *see* heat shock proteins
 HSP27
 – expression in blood vessels 308
 – isoelectric isoforms 301
 HSV *see* human saphenous vein
 HTS *see* high-throughput screening
 HUGO *see* Human Genome Organisation
 Humalo *see* insulin
 human B-type natriuretic peptide (BNP) 117, 119–120
 human body fluids, clinical neuroproteomics 259–272
 human brain, 2D-protein map 289
 human brain proteome project (HBPP)
 – national genome research network 11–14
 – pilot phase 15–16
 – proteome organisation 14
 human breast cancer cell line, MCF-7 243
 human breast cancer cells, drug resistance 241–254
 human genome
 – high-throughput subcloning 142–143
 – sequencing 113
 Human Genome Organisation (HUGO) 14
 Human Genome Project (HGP), peptide research 115
 human growth hormone, peptide-based pharmaceutical 117
 human mitochondrial proteome 302
 human parathyroid hormone, peptide-based pharmaceutical 117
 human platelets *see* platelets
 Human Proteome Organisation (HUPO), initiation 14
 Human Proteome Resource (HPR), Swedish 144
 human saphenous vein (HSV) 309
 human sputum, peptide and small protein map 108
 human umbilical vein endothelial cells (HUVECs) 308
 – cultured 310
 human urine, solid phase extraction (SPE) 100
 humanized antibodies 150
 humoral autoimmune repertoire, dilated cardiomyopathy (DCM) patients 145
 Humulin *see* insulin
 HUPO *see* Human Proteome Organisation
 HUPO Brain Proteome Project (BPP) 3
 – Data Collection Center (DCC) 13
 HUPO Proteomics Standards Initiative (PSI)
 – data model 24
 – initiation 14
 HUVECs *see* human umbilical vein endothelial cells
 hydrophilic interaction (HILIC), MD-LC selective filters 90, 94
 hydrophobic domains, membrane proteins 247
 hydrophobic interaction (HIC), MD-LC selective filters 90, 94
 hydrophobicity, MD-LC protein separation 95
 hyperphosphorylation, tau protein 264
 hypertrophy, cardiac 301
- i*
 IC₅₀ values
 – *in vitro* activity testing 190
 – fluorescence polarization 167
 – structure–activity relationship 200–201
 ICAT *see* isotope-coded affinity tags
 ICPL *see* isotope-coded protein label
 IEC *see* ion exchange chromatography
 IEF *see* isoelectric focusing
 IEX *see* ion exchange
 IgGs, high-abundance proteins 105–106
 IMAC *see* immobilized metal affinity chromatography
 image analysis software
 – 2-DE 35
 – DIGE 37
 ImageMaster 2D Elite, protein quantification software 283
 imaging cyler robots 177–179
 Imatinib *see* Gleevec
 immobilized metal affinity, MD-LC selective filters 94
 immobilized metal affinity chromatography (IMAC)
 – MD-LC selective filters 90

- phosphorylated peptides 106
- immobilized pH gradient (IPG)
 - 2D-protein map of human brain 289
 - brain sample 2D electrophoresis 281–283
 - DIGE blood assays 271
 - heart cells 302, 311
 - in 2-DE 34
 - vessel cell proteomics 309
- immortalized cells, human saphenous vein (HSV) 310
- immune response processes, cells involved 193
- immunoassay, micro format 149
- immunoblot
 - anti-phosphotyrosine 214
 - cerebrospinal fluid A β peptides 262
- immunodetection, phosphoprotein visualization 209
- immunoglobulins, removal for proteomic analysis 102
- immunosorbent assays, enzyme-linked *see* ELISA
- impaired prohormone processing 128
- in silico*-generated data, peptide masses 66, 123
- in situ*-labeling, metabolic 69
- in vitro* activity testing, SMART target identification 190
- in vitro* characterization, protein interactions 159–171
- in vivo* methylation, HeLa cell proteins 72
- in vivo* models, peptidomics 127–128
- infections, viral 300
- inflammatory processes, cells involved 193
- inhibition, pharmacological 304
- inhibitors database, MEROPS 125
- inhibitory concentration 50% *see* IC₅₀ values
- initial feasibility confirmation 329
- innovation, definition 321
- innovation process 321–335
 - criteria 322
 - deliverables 326–326
- insulin
 - diabetes biomarker 119
 - peptide-based pharmaceutical 117
 - therapeutic peptide 113
- IntAct
 - protein–protein interaction database 27
 - public domain database 24
 - UniProt cross-reference 21
- intact human platelets, PKG-dependent phosphorylation 217
- intact proteins, map 299
- intact vessels, proteomics 307–311
- Integr8, browser 22
- intellectual property 324
- interconversion, dimeric–tetrameric 198–199
- interferon- β , peptide-based pharmaceutical 117
- international protein index (IPI), protein analysis tools 23
- InterPro, protein analysis tools 22
- intra vitam* diagnosis, dementia 271
- ion exchange (IEX), MD-LC selective filters 90, 94
- ion exchange chromatography (IEC) 95
 - protein separation 99
- ion formation, biological mass spectrometry 62
- ionization
 - biological mass spectrometry 58–62
 - electrospray *see* electrospray ionization
 - peptides 121
- IPG *see* immobilized pH gradient
- IPI *see* international protein index
- iron-binding protein p97, possible Alzheimer's disease biomarkers 267
- isoelectric focusing (IEF)
 - in 2-DE 34
 - MD-LC sample clean-up 94
- isoelectric isoforms, heat shock protein HSP27 301
- isoelectric point (pI)
 - isoelectric focussing *see* isoelectric focusing
- isoforms
 - atrial 306
 - isoelectric 301
- isolated vessel cells, proteomics 308–310
- isotachopheresis (ITP), MD-LC sample clean-up 94
- isothermal titration calorimetry (ITC)
 - *in vitro* characterization of protein interactions 161
 - comparison with other biomolecular interaction analysis methods 170
 - in drug design 163–165
 - ligand binding analysis 164
 - thermodynamic characterization of drug–therapeutic target interactions 163
 - typical experiment 165
- isotope-coded affinity tags (ICAT) 73
 - multicolumn chromatography separation 106
- isotope-coded protein label (ICPL), chemical labeling 74–76
- isotope-labeled amino acids, introduction into cultured cell 249
- isotope labeling, chemical 73–74

- isotope signature, generation for MS samples 69
- ITC *see* isothermal titration calorimetry
- ITP *see* isotachopheresis
- iTRAQ reagent, chemical labeling 76
- IUPAC–IUB Joint Commission on Biochemical Nomenclature 116
- k**
- karyotyping, spectral 225
- keratinocyte lipid-binding proteins, LPS-stimulatory effect 194
- Ki-67, renal cell carcinoma (RCC) biomarkers 229
- kidney epithelium
- heterogeneous annexin IV expression 234
 - representative 2-DE map 233
- kidney malignancy *see* renal cell carcinoma
- kinase Ste20, phosphorylation 70
- kinetic proteome changes, identification 39–43
- kinetics, regulated proteins 41
- knock out mouse model
- molecular networks analysis 182
 - phosphoproteome differences to wild type mice 218–219
 - tau gene 263–264
- knowledgebase, UniProt 21
- KO mice *see* knock out mouse model
- Krebs cycle, mitochondria 303
- l**
- label cleavage, β -elimination 73
- labeling
- *in situ* 69
 - ^{15}N 70–71
 - chemical 73–77
 - CyDye DIGE minimal fluors 39
 - CyDye DIGE saturation fluors 44
 - metabolic 69–73
 - stable isotope 71–72, 75–77
- labeling protocol, DIGE minimal fluors 38
- lactate generation, inhibition by A 77 1726 199
- lactic dehydrogenase (lactic DH, LDH)
- binding diagram 197
 - glycolytic enzyme complex 196
 - leflunomide-binding proteins 192
- language metaphor, protein–toponome relationship 174–176
- large-scale protein identification, Mascot/Sequest algorithm 67
- laser capture microdissection (LCM) 311
- LC-MS/MS, protein detection in amyloid plaques 284
- LCM *see* laser capture microdissection
- LDH *see* lactic dehydrogenase
- lead compound identification
- materials and methods 190–193
 - SMART 187–203
- lead proteins, toponome mapping 180
- leflunomide, rheumatoid arthritis (RA) treatment 189
- leflunomide-binding proteins 192
- leflunomide derivative A 95 0277, molecular structure 191
- leflunomide metabolite A 77 1726
- AF eluted protein fraction 195
 - direct metabolic effects 200
 - inhibition of lactate generation 199
 - molecular structure 191, 200
 - structure–activity relationship with acyl cyanides 201
- lepirudin, peptide-based pharmaceutical 117
- Lewy body dementia, discrimination from Alzheimer’s disease 265–266
- life expectancy, increase 259
- life science
- commercialization 5–6
 - increasing complexity 4
- ligand A/B 166–167
- ligand activation, trk-receptors 39–43
- ligand binding analysis, isothermal titration calorimetry (ITC) 164
- ligand–receptor interactions, high-throughput screening 151
- Lignum nephriticum*, fluorescence 165
- lipid metabolism, mitochondria 303
- lipid peroxidation, neurodegenerative pathologies 293
- liquid chromatography
- coupled with MALDI MS 59–60
 - MD-LC/MS methods 91–92
 - workflow strategy options 99
 - *see also* HPLC
- liver proteome project (LPP) 14
- lobby work 4
- localization
- phosphorylated residue 211
 - phosphorylation sites of cortactin and myosin RLC 215
- logarithm, graph (for data normalization) 49
- lognormal distribution, DIGE data statistical analysis 50
- LPP *see* liver proteome project
- luminescence signal generation, AlphaScreen assay 168

- luteinizing hormone–releasing hormone (LH–RH)
 - agonists 118
 - discovery 115
- lymphocyte glycoprotein CD26 126
- lysis buffer, DIGE minimal fluors 38
- m**
- M2-PK, proliferating tumor cells 198
- macrophage cell line *see* RAW 264.7 cell line
- MafK transcription factor 80
- MALDI 57–60
 - imaging 60
 - peptide ionization techniques 121
 - sample preparation 58
- MALDI-PMF, protein identification 302–304, 306
- MALDI qTOF, schematic representation 64
- MALDI-TOF MS
 - *Drosophila* hemolymph spectra 122
 - accelerating voltage 283
 - Alzheimer’s disease proteomics 283–284
 - chromatographic platform configuration 108
 - mitochondrial proteome studies 303
 - rat neurointermediate lobes spectra 122
- MALDI TOF/TOF, schematic representation 64
- malic dehydrogenase (malic DH, MDH)
 - binding diagram 197
 - leflunomide-binding proteins 192
- map, intact proteins 299
- MAPK *see* mitogen-activated protein kinase
- MAPKAP kinase 2/5 deficient mice 218–219
- mapping, molecular networks as patterns 176–177
- MAPs *see* microtubule-associated proteins
- mark-up language, PSI-ML 25
- markers
 - acute allograft rejection 307–307
 - diagnostic 279
 - neurochemical 260–272
- market attractiveness 323
- market data 323
- market position
 - competitive 323–324
 - leading 328
- market preparation 319–335
 - innovation process 334
- Mascot algorithm, large-scale protein identification 67
- mass fingerprints, peptides 123
- mass loadability
 - ion exchange chromatography (IEC) columns 95
 - MD-LC columns 97
- mass spectrometry
 - biological *see* biological mass spectrometry
 - data interchange formats 25–27
 - differential nuclear protein abundances 251
 - instrumentation 62–65
 - MD-LC/MS methods 91–92
 - novel search Alzheimer’s disease biomarker techniques 270–271
 - proteomic data handling 25–27
 - quantitative 67–69, 78–81
- matrix-assisted laser desorption/ionization *see* MALDI
- matrix-assisted laser desorption/ionization time-of-flight mass spectroscopy *see* MALDI-TOF MS
- maximum-likelihood estimation, DIGE data statistical analysis 49
- MCF-7 cells
 - 2D gel array of nuclear proteins 248
 - breast cancer cell line 120
 - colloidal silica method 246
 - differential nuclear protein abundance 252
 - drug resistant 252–254
 - parental cell line 243
 - plasma membrane protein abundance changes 253
- MCI *see* mild cognitive impairment
- MD *see* multicolumn chromatography
- MD-LC
 - “digestion-free” strategy 99
 - column miniaturization 97
 - direct injection of biological samples 107
 - performance parameters 96
 - phase system choice 94–96
 - present situation 89–109
 - selective reversed phase (RP) filters 90, 94
- MD-LC columns, mass loadability 97
- MD-LC fractionation, protein mixtures 101
- MD-LC separation, applications 100–104
- MD-LC/MS methods
 - advantages 91–92
 - desired outcome 93–94
 - development 92–100
 - general aspects 92–93
- MD protein identification technology (MudPIT) 101–102
- MDH *see* malic dehydrogenase

- “me too” producer, innovation process
 - concept 323
- meaning, codified in biological systems 174
- medical research, differential
 - phosphoproteome analysis 209–219
- medicinal chemistry, CMPC 203
- megakaryocytes, bone marrow 210
- MELK *see* multiepitope ligand kartographie
- membrane
 - cell surface 181
 - plasma 252–254
- membrane brain proteins, sample
 - preparation 281
- membrane-impermeable biotinylating
 - reagent, chemical labeling 74
- membrane proteins, hydrophobic domains 247
- membrane pumps, ATP-dependent 242
- membrane trafficking proteins, enriched in amyloid plaques 294
- MEROPS, proteases and inhibitors database 125
- metabolic flux, RAW264.7 cell line 199
- metabolic labeling
 - biological mass spectrometry 68–73
 - mapping of protein complexes 79
 - quantitative protein abundance comparison 249
 - yeast cells 70
- metabolism
 - β -APP 261–263
 - lipid 303
- methotrexate, drug resistance 243
- methyl-5-cyano-3-methyl-5-oxopentanoate, SMART target identification 193
- methyl-5-cyano-5-oxopentanoate, SMART target identification 192
- methyl-6-cyano-6-oxohexanoate, SMART target identification 193
- MGED *see* Microarray Gene Expression Data consortium
- Miacalcin *see* calcitonin
- MIAME *see* minimum information about a microarray experiment
- MIAPE guidelines, General Proteomics Standards (GPS) 25
- mice
 - phosphoproteome differences 218–219
 - *see also* mouse
- micro format immunoassay, antibody arrays 149
- microarray gene expression (MAGE), object model and XML implementation 25
- Microarray Gene Expression Data (MGED) consortium 24
- microarrays
 - DNA technology 137
 - gold-coated 140
 - schematic representation 144
- microdissected cells
 - molecular tumor marker analysis 45–47
 - PanIN-2 46
- microdissection, laser capture 311
- β -2 microglobulin, renal failure biomarker 119
- microtubule-associated proteins (MAPs) 263–264
- migration status, functional cell states 178–179
- mild cognitive impairment (MCI)
 - Alzheimer’s disease preliminary stage 266
 - prediction of development 269–270
- minimal CyDye gel, Cy5/Cy3 spot volumes 48
- minimal labeling, CyDye DIGE minimal fluors 38–44
- minimum information about a microarray experiment (MIAME) guidelines 25
- MINT, protein–protein interaction database 27
- MIPS, protein–protein interaction database 27
- mitochondria
 - heart proteomics 302–305
 - isolation 244
- mitochondrial brain proteins, sample
 - preparation 281
- mitochondrial dysfunction 302
- mitochondrial proteome, human 302
- mitogen-activated protein kinase (MAPK) 218
- mitoxantrone
 - drug resistance 252–254
 - molecular structure 244
 - resistant and susceptible cells 251
- mitoxantrone resistant MCF-7 cells, plasma membrane protein abundance changes 253
- MLC *see* myosin light chains
- MLCK *see* myosin light chain-kinase (MLCK)
- model system, protein interactions 161–161
- modern science, complexity 4
- modification, oxidative 291
- molecular interactions, proteomic data handling 27
- molecular markers
 - PanIN-2 DIGE 47
 - risk biomarkers 228

- tumor 45–47
 - molecular networks
 - cell surface membrane 181
 - in morphologically intact cells and tissue 173–182
 - mapped as patterns 176–177
 - toponome mapping 180
 - Monardes, Nicolás 165
 - mouse, knock out *see* knock out mouse model
 - mouse embryonic cardiac fibroblasts 218
 - mouse model, multiple sclerosis 146
 - mouse monocyte/macrophage cell line
 - see* RAW 264.7 cell line
 - mouse proteome database, RefSeq 23
 - mRNA, degradation processes 122
 - MS *see* mass spectrometry, multiple sclerosis
 - MudPIT *see* MD protein identification technology
 - multicolumn affinity chromatography 107
 - multicolumn chromatography
 - chromatographic platform configuration 108
 - *see also* MD-LC
 - Multidimensional Column Liquid Chromatography *see* MD-LC
 - multiepitope ligand kartographie (MELK)
 - development 176
 - toponome data sets 180
 - multimodal approach, biomarker discovery 225
 - multiparametric biomarker analysis 223
 - multiple sclerosis
 - cerebrospinal fluid analysis 267
 - mouse model 146
 - multiple system atrophy, discrimination from Alzheimer's disease 265
 - multiplex technology, in comparison to ELISA 271
 - multiplexing, novel search Alzheimer's disease biomarker techniques 270–271
 - multistage chromatography *see* MD, MD-LC
 - murine monocyte/macrophage cell line
 - see* RAW 264.7 cell line
 - muscle cells, subcellular toponome fingerprint 178
 - mutated genes, neurodegenerative disorders 280
 - myocytes, cardiac 305–306
 - myosin, regulatory light chain (RLC) 213–214
 - myosin light chain-kinase (MLCK) 213
 - myosin light chains (MLC), cultured cardiac myocytes 306
 - myosin regulatory light chain (MRCL) 3, DIGE molecular markers 47
 - mzData, mass spectrometry data format 25–27
- n**
- N-hydroxysuccinimid-ester (NHS-ester) 39
 - N-terminal-pro BNP (NT-proBNP), congestive heart failure biomarker 119
 - ¹⁵N labeling
 - biological mass spectrometry 70–71
 - yeast cells 70
 - ¹⁵N₄-arginine, stable isotope labeling 71
 - NAD concentration, cell death 202
 - nano-LC MS/MS, human platelets phosphoproteomics 213
 - nanowell microarrays, enzyme activities 148
 - nasopharyngeal carcinoma biomarker, EBV 228
 - national genome research network, human brain proteome project 11–14
 - National Genome Research Network (NGFN) 3
 - initiation 11
 - National Institutes of Health
 - definition of biomarkers 228
 - UniProt 21
 - Natreco *see* nesiritide
 - NDK-A, reduced level in Alzheimer's disease 291
 - neonatal cardiac myocytes 305
 - nephrectomy 229–230
 - nerve cells, nonspecific disruption 265
 - nesiritide, peptide-based pharmaceutical 117
 - net present value (NPV), innovation process reward 325, 333
 - network
 - human brain proteome project 11–14
 - proteomics in drug development 9–10
 - network motifs, formalization as geometric objects 179–181
 - networking
 - proteomics 6–7
 - realization in brain proteome projects 10–16
 - neuroblastoma SY5Y, cell line 39
 - neuroborreliosis, cerebrospinal fluid analysis 267
 - neurochemical markers, alzheimer's disease 260–272
 - neurodegeneration 279
 - *see also* AD, dementia
 - neurodegenerative disorders, mutated genes 280

neurofibrillary tangles (NFT), Alzheimer's disease neuropathological markers 260
 neuroimaging studies, Alzheimer's disease diagnosis 260
 Neuronal thread proteins (NTPs), possible Alzheimer's disease biomarkers 267
 neuropathological markers, Alzheimer's disease 260
 neuroproteomics, clinical 259–272
 neurotrophin
 – 2D-DIGE 41–43
 – NGF/BDNF 39
 NGFN *see* National Genome Research Network
 NIH Biomarker Definitions Working Group 118
 3-nitrotyrosine formation, neurodegenerative pathologies 293
 non-Alzheimer dementia types 265, 268
 noncovalent homodimer, protein disulfide isomerase (PDI) 214
 nondementive neurologic diseases (OND), discrimination from Alzheimer's disease 269
 nonphosphorylated peptides, fragment ion spectra 215
 nonredundant cDNA expression library, German Human Brain Proteome Project 11
 nonspecific nerve cell disruption, cerebrospinal fluid tau increase 265
 noreceptor tyrosine kinases 189
 norepinephrine treatment, protein expression 305
 normalization, protein expression data 48–50
 novel search techniques, Alzheimer's disease biomarkers 270–271
 NT-proBNP *see* N-terminal-pro BNP
 NTP *see* Neuronal thread proteins
 nuclear matrix proteins, up-regulated in renal cell carcinoma (RCC) 229
 nuclear protein changes, drug resistant MCF-7 cells 252–254
 nuclear proteins
 – 2D gel array 248
 – differential abundances 251–252
 nucleolin
 – differential abundance in mitoxantrone resistant MCF-7 cells 252
 – differential nuclear protein abundances 251
 nucleophosmin, differential nuclear protein abundances 251

nucleoside diphosphate kinase-A *see* NDK-A
 NVP *see* net present value

o

object model
 – microarray gene expression (MAGE) 25
 – PSI-OM 25
 Octreotide *see* somatostatin
 offline fractionation, strong cation exchange chromatography 101
 oligopeptides, definition 116
 OND *see* nondementive neurologic diseases
 operational aspects, MD-LC/MS methods 97–98
 optimization
 – pre-piloting 334
 – proteomics networks 3–16
 organelle proteomics
 – drug resistance studies 241–254
 – objectives and experimental design 243–252
 osteocalcin, osteoporosis biomarker 119
 ovarian surface epithelial cells, protein content 104
 overexpression, peroxiredoxins 293
 oxidation, DNA and proteins 293
 oxidative modification, dihydropyrimidinase-related protein (DRP-2)
 oxidative stress, neurodegenerative pathologies 293
 oxidized proteins, Alzheimer's disease proteomics 292–293
 oxytocin, discovery 115

p

P-glycoprotein (Pgp), drug resistance protein contributors 242
 [³²P]-orthophosphate, radiolabeling 209
 p38 mitogen-activated protein kinase (MAPK) pathway 218
 p97, iron-binding protein 267
 paired *t*-test, power-function 52
 pancreatic ductal adenocarcinoma, precursor lesions 45
 pancreatic ductal epithelium, DIGE analysis 46
 pancreatic intraepithelial neoplasias *see* PanIN
 PanIN
 – analysis of microdissected cells 45–47
 – stained histological images 45
 PanIN-2 microdissected cells, DIGE analysis 46–47
 parathyroid hormone, human 117

- parenchyma, brain 260
- parental cell line, MCF-7 243
- parietal cortex, 2D-protein map 290
- Parkinson's disease
 - discrimination from Alzheimer's disease 265
 - HBPP2 12
- PARP-1, differential abundance in mitoxantrone resistant MCF-7 cells 252
- patterns, maps of molecular networks 176–177
- PCT *see* procalcitonin
- PDAC *see* pancreatic ductal adenocarcinoma
- PDI *see* protein disulfide isomerase
- PEG *see* polyethylene glycol copolymer
- peptide analytical methods, evolution 120–121
- peptide-based diagnostics and biomarkers 119
- peptide-based pharmaceuticals 117
- peptide content, influenced by coagulation 119
- peptide identification, body fluids 123
- peptide ionization techniques 121
- peptide labeling, schematic representation 68
- peptide map
 - human sputum 108
 - MD-LC/MS 100
- peptide mass fingerprints (PMF) 123
 - biological mass spectrometry 63, 66
- peptide masses, *in silico*-generated data 66, 123
- peptide microarrays
 - enzyme activities 148
 - schematic representation 144
- peptide-processing peptidase, DPPIV 126
- peptide research
 - analytical chemistry 121
 - blood 118
 - history 114–115
- peptide separation, SEC/RPC combination 103
- peptides
 - bioactive 120
 - biomarkers 118
 - brief biochemistry 116
 - definition 116
 - differential display process 128
 - drug research 114–120
 - drugs 117–118
 - endogenous 123–124
 - phosphorylated 106
 - stable isotope labeling 75–77
 - word origin 114
- peptidomics
 - *in vivo* models 127–128
 - clinical 118–120
 - differential display 124–128
 - drug development 124–127
 - first introduction 115
 - future developments 129–130
 - profiling 121–123
 - technologies and applications in drug research 113–130
- peptidomics screening, fully automated 2D-LC system 109
- peptidomics technologies, development 120–124
- peroxidation, lipid 293
- peroxiredoxins, overexpression 293
- Perrin equation 166
- Pfam, protein database 22
- Pgp *see* P-glycoprotein
- pharmaceutical research and development 150–151
- pharmaceutical screening tool, AlphaScreen 167–169
- pharmaceuticals, peptide-based 117
- pharmacological inhibition, PKC 304
- phase III, clinical trials 124
- phase system, choice in MD-LC 94–96
- phospho-HSP 25, mouse cardiac fibroblasts 219
- phosphoglycerate mutase, glycolytic enzyme complex 196
- phosphoproteins
 - quantitation 75
 - visualization 209
- phosphoproteome analysis
 - 2D-PAGE 209–210
 - differential 209–219
 - future developments 219
- phosphoproteome differences, wild type and knock out mice 218–219
- phosphoproteomics, human platelets 211–216
- phosphor-imaging (³²P, ¹⁴C and ³⁵S), 2-DE staining methods 35
- phosphorylated human platelet proteins, autoradiography 212
- phosphorylated peptides
 - fragment ion spectra 215
 - immobilized metal affinity chromatography (IMAC) 106
- phosphorylated residue, localization 211
- phosphorylated tau protein 263–266

- as Alzheimer's disease biomarker 265–266
- phosphorylation
 - kinase Ste20 70
 - PKG-dependent 217
 - protein 209
 - serine 262 264
- phosphorylation sites
 - cortactin 215
 - myosin RLC 215
- phosphospecific dyes, staining 209
- pI *see* isoelectric focusing, isoelectric point
- PIC, preinitiation complex 80
- picomole range, sample concentrations 59
- pilot phase, human brain proteome project 15–16
- PIR *see* Protein Information Resource
- PKA
 - AlphaScreen assay 169
 - as model system 161–161
 - identification and function in human platelets 217
 - tetrameric holoenzyme 161
- PKA regulatory subunit, binding analysis 162–163
- PKA substrates, human platelets 216–218
- PKC
 - pharmacological inhibition 304
 - signal transduction pathways 304–305
- PKC- ϵ complex 304–305
- PKG, identification and function in human platelets 217
- PKG-deficient mice 216
- PKG-dependent phosphorylation, intact human platelets 217
- PKG substrates, human platelets 216–218
- plaques
 - Alzheimer's disease neuropathological markers 260
 - amyloid 293–294
- plasma membrane isolation
 - immobilized streptavidin carrying beads 245
 - proteomic drug resistance studies 245–246
- plasma membrane proteins
 - abundance changes 253
 - analysis 247
 - drug resistant MCF-7 cells 252–254
 - enrichment 245–246
 - up-regulated BCRP 254
- plasma proteome project (PPP) 14
- platelets
 - adhesion 211
 - cGK activation 216
 - human 211–218
 - origin 211
 - phosphoproteomics 211–216
 - phosphorylated proteins autoradiography 211–212
 - PKA/PKG substrates 216–218
 - PKG-dependent phosphorylation 217
- PMF *see* peptide mass fingerprint
- Pol II *see* RNA polymerase II
- polarization *see* fluorescence polarization
- polyacrylamide gel electrophoresis *see* 1D-PAGE, 2D-PAGE
- polyethylene glycol copolymer (PEG), protein biochips surface coating 139–140
- portfolio targets, fit with concept 322, 325
- postmortem brain samples 280
- postsorce decay (PSD), biological mass spectrometry 62
- posttranslational modification (PTM) 20
 - protein phosphorylation 210
 - protein–protein interaction MS 80
- PP *see* progressed project
- pp60c-src, tyrosine kinase 213
- PPP *see* plasma proteome project
- pre-piloting optimization stage, innovation process 334
- preanalytical confounding factors, cerebrospinal fluid analysis 270
- preinitiation complex (PIC), RNA polymerase II (Pol II) 80
- premortem diagnostic marker, Alzheimer's disease 279
- PRIDE, database 15
- PRINTS, protein database 22
- pro-opio-melanocortin (POMC), hormone precursor 116
- procalcitonin (PCT), bacterial infection/sepsis biomarker 119
- ProDom, protein database 22
- profiling
 - antibody repertoire 146
 - peptidomic 121–123
 - proteome analysis 10
- ProFIT *see* project financial information table
- prognostic markers, evaluation 7–8
- progressed project (PP) stage, innovation process 331–333
- progressive supranuclear palsy, discrimination from Alzheimer's disease 265
- prohibitin, differential abundance in mitoxantrone resistant MCF-7 cells 252
- prohormone processing, impaired 128
- proinsulin, diabetes biomarker 119

- project financial information table (ProFIT), innovation process reward 333
- proliferating tumor cells, M2-PK expression 198
- Proof of Concept Fund, Scotland 5
- property, intellectual 324
- PROSITE, protein database 22
- proteases, enriched in amyloid plaques 294
- proteases and inhibitors database, MEROPS 125
- protein abundances, quantitative comparison 249–252
- protein analysis, tools 21–23
- protein arrays, reverse phase 148
- protein biochips 137–151
 - generation 142
 - in comparison to ELISA 146
 - protein–biomolecule interaction screening 138
 - surface coating 139–140
- protein classes, underrepresented in 2-D gels 294
- protein complexes, purification 78
- protein content, ovarian surface epithelial cells 104
- protein databases, gel 300
- protein derivatization, covalent 36
- protein detection
 - 2-DE/DIGE 36–52
 - amyloid plaques 284
- protein diffusion, cerebrospinal fluid-flow rate-related 272
- protein disulfide isomerase (PDI)
 - differential phosphoproteome analysis 214–216
 - noncovalent homodimer 214
- protein enrichment, plasma membrane 245
- protein expression data, calibration and normalization 48–50
- protein fingerprint, multiepitope ligand kartographie (MELK) 177
- protein fractionation
 - A 77 1726 195
 - proteomic drug resistance studies 247–249
- protein identification
 - biological mass spectrometry 65–67
 - MALDI-PMF 304
 - Mascot/Sequest algorithm 67
 - proteomic drug resistance studies 247–249
 - SMART 191
- protein immobilization and surface chemistry 139–141
- Protein Information Resource (PIR) 21
- protein interactions
 - *in vitro* characterization 159–171
 - real-time monitoring 161–163
- protein kinase
 - cAMP-dependent 161–161
 - cAMP- and cGMP-dependent 216–218
- protein kinase C *see* PKC
- protein labeling, schematic representation 68
- protein map
 - small proteins 108
 - two-dimensional 289–290
- protein microarrays
 - antibody repertoire profiling 146
 - enzyme activities 148
 - performance 139
 - protein–ligand interaction studies 147
 - schematic representation 144
- protein mixtures
 - analysis 33
 - complex 90
 - MD-LC fractionation 101
- protein patterns, functional cell units 177
- protein phosphorylation, reversible posttranslational modification 210
- protein profiles, comparison with cellular protein patterns 178
- protein quantification, Alzheimer’s disease proteomics 282–283
- protein separation, ion exchange chromatography (IEC) 99
- protein–biomolecule interactions, screening with protein biochips 138
- protein–ligand interactions, protein microarrays 147
- protein–protein interaction
 - biochip studies 143
 - databases 27
 - role of protein phosphorylation 210
- proteins
 - 14-3-3 291–292, 294
 - actin-binding 213
 - antioxidant 293
 - BCR-ABL 171
 - cardiac 300–301
 - chemical isotope labeling 73–74
 - CNPase 291
 - composition and properties 138
 - contextual nature and functional coding principle 174
 - definition 116
 - differentially expressed 50–51, 234
 - dihydropyrimidinase-related 284
 - double inhibition 181

- enriched in amyloid plaques 293–294
 - glial fibrillary acidic protein (GFAP) 287, 290
 - guidance 291
 - heat shock *see* heat shock proteins (HSP)
 - high-resolution separation 34
 - immobilization in biochips 141
 - kinase Ste20 70
 - leflunomide-binding 192
 - NDK-A 291
 - nuclear 252–254
 - oxidized 292–293
 - proteolytic processing 113
 - signal transduction 291–292
 - snap 25 290
 - stathmin 288, 291
 - synaptosomal 290–291
 - tau 263–266
 - ubiquitination 302
 - with deranged levels and modifications in Alzheimer's disease and/or DS 284–294
 - word origin 114
 - ProteinScape, data handling software 15
 - protein–toponome relationship
 - language metaphor 174–176
 - syntax 175
 - proteolytic processing
 - hormone precursors 116
 - proteins 113
 - proteome analysis
 - “bottleneck” sample clean-up 104–109
 - Alzheimer's disease 280–284
 - disease-oriented 9
 - four steps 105
 - protein analysis tools 22–23
 - statistical aspects 47–52
 - Proteome Standards Initiative
 - see* HUPO PSI
 - proteomes
 - brain project 10–16
 - dynamic range 91
 - kinetic changes 39–43
 - mitochondrial 302
 - profiling 10
 - renal cell carcinoma 223–235
 - word origin 34
 - PROTEOMEX
 - disease-related information 227
 - renal cell carcinoma (RCC) biomarkers identification 232
 - proteomic characterization, cardiac antigens 306
 - proteomic data
 - mass spectrometry 25–27
 - standardization, deposition and exchange 19–21
 - proteomic drug research
 - applications 187–312
 - from target to lead synthesis 187–203
 - proteomic technologies 31–182
 - proteomic workstation, fully integrated 12
 - proteomics
 - Alzheimer's disease 279–294
 - cardiac 299–312
 - cultured cardiac myocytes 305–306
 - DS 280
 - liquid chromatography workflow strategy options 99
 - MD-LC 89–109
 - networking 6–7
 - quantitative 67
 - recent advances 209
 - state-of-the-art in 2005 90
 - system-oriented 138
 - top-down approach 90
 - unbiased or discovery-oriented 138
 - vessel 307–312
 - proteomics networks
 - administrative optimization 3–16
 - drug development 9–10
 - proteomics response, drug resistance 242–243
 - proteomics technologies, high resolution 188
 - PSI-ML, mark-up language 25
 - PSI-MS, mass spectrometry data format 25–26
 - PSI-MS XML, data interchange format 26
 - PSI-OM, data object model 25
 - pTau181, increased in Alzheimer's disease cerebrospinal fluid 265
 - PTM *see* posttranslational modification
 - public domain databases
 - BIND 24
 - DIP 24
 - IntAct 24
 - public relations 5
 - pyrimidine biosynthesis, DHODH 195
 - pyruvate kinase
 - binding diagram 197
 - glycolytic enzyme complex 196
 - leflunomide-binding proteins 192
 - type M2 *see* M2-PK
- q**
- quadrupole TOF (qTOF), analyzer 60, 63–66
 - protein identification 75, 77
 - *see also* MALDI, TOF

- quantitative mass spectrometry
 - comparative and functional proteomics 67–69
 - protein–protein interactions 78–81
- quantitative protein abundance comparison, schematic representation 250
- quantitative proteomics, strategies 67
- quinine, fluorophore 165

- r**
- R&D resources, innovation process concept 322–323
- RA *see* rheumatoid arthritis
- radioimmunoassay (RIA) 114, 120
- radioisotopes, biochip signal amplification 142
- radiolabeling, [³²P]-orthophosphate 209
- RAM *see* restricted access materials
- RAM-SCX column, chromatographic platform configuration 108
- random forest clustering, tumor profiling strategy 230
- rapid monitoring, renal cell carcinoma (RCC) patients 235
- RAT HEART-2DPAGE, 2-D protein databases 300
- rat neurointermediate lobes, MALDI-TOF-MS spectra 122
- rat proteome database, Ensembl 23
- RAW 264.7 cell line
 - culture medium 190
 - flux of the major metabolites 199
 - immune response and inflammatory processes 193
- Rayleigh limit, electrospray ionization 60–61
- RCA *see* rolling circle amplification
- RCC *see* renal cell carcinoma
- reactome, protein analysis tools 23
- real-time monitoring, protein interactions 161–163
- recombinant hirudin, peptide-based pharmaceutical 117
- Refluda *see* lepirudin
- RefSeq, mouse proteome database 23
- regulated proteins
 - kinetics 41
 - SY5Y-TrkA(B) DIGE 42–43
- regulatory light chain, myosin 213–214
- renal cell carcinoma (RCC)
 - biomarker discovery 223–235
 - biomarkers identification 231–232
 - cell lines and biopsies proteome analysis 229–233
 - diagnostics and pathology 224
 - heterogeneous annexin IV expression 234
 - rapid patient monitoring 235
 - representative 2-DE map 233
- research network, human brain proteome project 11–14
- restricted access materials (RAM)
 - first published 107
 - solid phase extraction 94
- return on capital employed (ROCE), innovation process reward 325, 333
- reverse phase protein arrays (RPPA) 148
- reversed phase (RP) analytical column, chromatographic platform configuration 108
- reversed phase chromatography (RPC) 90
 - MD-LC second dimension 95, 99
 - peptide separation 103
- reversible posttranslational modification, protein phosphorylation 210
- rheumatoid arthritis (RA)
 - autoantibody patterns 146
 - novel drug CMPC 199
 - SMART target identification 188
- rhodamin B, cell stain 165
- RIA *see* radioimmunoassay
- risk categories, innovation process 328, 330
- RNA polymerase II (Pol II), preinitiation complex (PIC) 80
- “RNA silencer”, hnRNP K 43
- robotic systems, multiepitope ligand kartographie (MELK) 177
- robots, imaging cycler 177–179
- ROCE *see* return on capital employed
- rolling circle amplification (RCA), biochips 142
- RPC *see* reversed phase chromatography
- RPPA *see* reverse phase protein arrays
- RUBITEC, Society for Innovation and Technology 6
- Ruhr University Bochum 6

- s**
- 40S ribosomal protein SA, differential abundance in mitoxantrone resistant MCF-7 cells 252
- Saccharomyces cerevisiae*, high-throughput subcloning 142–143
- Saccharomyces cerevisiae* kinases, enzyme activities 148
- SAM *see* selfassembled layers
- sample clean-up
 - “bottleneck” in proteome analysis 104–109

- MD-LC/MS methods 94
- sample concentrations, picomole to femtomole range 59
- sample preparation
 - 2D-DIGE 41
 - Alzheimer's disease proteomics 280–282
 - MALDI 58
- sample size determination, DIGE data
 - statistical analysis 51–52
- samples, brain 280
- Sandimmune *see* cyclosporine
- Sandostatin *see* somatostatin
- saturation labeling, CyDye DIGE saturation fluors 44–47
- scientific administration, modern 4
- Scotland, Proof of Concept Fund 5
- screening
 - high-throughput *see* high-throughput screening
 - markers, evaluation 7–8
 - pharmaceutical tools 167–169
- SCX *see* strong cation exchange chromatography
- SDS electrophoresis *see* SDS-PAGE
- SDS-PAGE
 - affinity chromatography (AF) 195
 - cerebrospinal fluid A β peptides 262
 - HSV cell protein map 309
 - in 2-DE 34
 - SMART target identification 191
- SEC *see* size exclusion chromatography
- SEC/RPC combination, peptide separation 103
- α -/ β -/ γ -secretases, A β peptides release 261, 263
- secretin, discovery 115
- SELDI 60
 - peptidomic profiling 123
- SELDI-TOF MS, cerebrospinal fluid analysis 270
- selective filters, MD-LC 93–94
- selective MD-LC filters, reversed phase (RP) 90, 94
- selfassembled layers (SAM), protein biochips
 - surface coating 139–140
- semantic structures, cell proteome 175
- sensitivity
 - A β 1-42 as Alzheimer's disease marker 262
 - MD-LC advantages 92
- sensor chip CM5, surface matrix activation 191
- sensor surface, functionalized 162
- separation
 - complex protein mixture 90
 - high-resolution 34
 - MD-LC 100–104
 - proteins 99
 - size exclusion chromatography (SEC) 104
 - septin 2
 - differential abundance in mitoxantrone resistant MCF-7 cells 252
 - differential nuclear protein abundances 251
- Sequest algorithm, large-scale protein identification 67
- serine 262, phosphorylation 264
- serological markers, disease-related information 228
- serological proteome analysis (SERPA) 227
- serology, renal cell carcinoma 223–235
- SERPA *see* serological proteome analysis
- serum proteomics, biomarker discovery 227
- “shotgun” proteomics, MD-LC 98
- signal amplification, biochips 142
- signal transduction pathways, PKC 304–305
- signal transduction proteins, Alzheimer's disease proteomics 291–292
- SILAC *see* stable isotope labeling by amino acids in cell culture
- silver, 2-DE staining methods 35
- size exclusion chromatography (SEC)
 - MD-LC selective filters 90, 94
 - separation efficiency optimization 104
- size-selective fractionation 107
- SLE *see* systemic lupus erythematosus
- small molecule adaptation on research targets *see* SMART
- small protein map, human sputum 108
- SMART
 - drug target and lead compound identification 187–203
 - materials and methods 190–193
 - protein database 22
 - results and discussion 193–203
 - schematic representation 188
- smooth muscle cells, isolated 308
- SMP *see* systematic methodical platform
- snap 25 288, 290–291
- software
 - bioinformatic data analysis 122
 - data analysis 165
 - data handling 15
 - protein quantification 283
- solid phase assay format, biomolecular interaction analysis 160
- solid phase extraction (SPE)
 - direct sample injection 106
 - human urine 100

- MD-LC sample clean-up 94
 - solution-based assay format, biomolecular interaction analysis 160
 - somatostatin
 - discovery 115
 - peptide-based pharmaceutical 117
 - Somatropine *see* human growth hormone
 - SOPs *see* standard operating procedures
 - SPE *see* solid phase extraction
 - spectral karyotyping, chromosomal aberration detection 225
 - Spectromania, bioinformatic data analysis software 122
 - spectrometry
 - biological mass *see* biological mass spectrometry
 - mass *see* mass spectrometry
 - proteomic mass spectrometry data 25–27
 - spectrum, peptide mass fingerprint 63
 - splicing, alternative 263
 - SPR *see* surface plasma resonance
 - sputum, peptide and small protein map 108
 - stable isotope labeling
 - at peptide level 75–77
 - mapping of protein complexes 79
 - schematic representation 68
 - stable isotope labeling by amino acids in cell culture (SILAC) 71–72
 - stage, innovation process 326
 - stage gate-like process 326
 - stained histological images, PanIN grades 45
 - staining
 - 2-DE 35
 - phosphospecific dyes 209
 - standard labeling protocol, DIGE minimal fluors 38
 - standard operating procedures (SOPs) 10
 - HBPP2 13
 - standardization, proteomic data 19–21
 - stathmin 288
 - reduced level in Alzheimer's disease 291
 - statistical test, possible results 51
 - Stokes' radius, MD-LC protein separation 95
 - stopped flow (SF) assays, *in vitro* characterization of protein interactions 161
 - stratification markers, evaluation 7–8
 - streptavidin, immobilized 245
 - streptavidin-coated donor beads 167, 169
 - strong cation exchange chromatography (SCX)
 - offline fractionation 101
 - protein mixtures identification 65
 - structure–activity relationship, A 77 1726 and acyl cyanides 201
 - subcellular localization 20
 - subcellular toponome fingerprint, muscle cells 178
 - subcloning, high-throughput 142
 - subproteomics, heart 302
 - SUPERFAMILY, protein database 22
 - surface coating, protein biochips 139–140
 - surface-enhanced laser desorption/ionization *see* SELDI
 - surface epithelial cells, ovarian 104
 - surface matrix activation, carboxymethylated sensor chip CM5 191
 - surface plasma resonance (SPR)
 - biosensors 160–163
 - comparison with other biomolecular interaction analysis methods 170
 - gold-coated microarrays 140
 - sustained alcohol abuse, dilated cardiomyopathy (DCM) contributory factors 300
 - comparative proteomics, usw 67–69
 - Swedish Human Proteome Resource (HPR) 144
 - Switzerland, biotechnology company concentration 7
 - SY5Y-TrkA(B) cell lysate, 2DE-gels 40
 - synaptosomal proteins
 - 25 kDa *see* snap25
 - Alzheimer's disease proteomics 290–291
 - synthesis
 - acyl chlorides 192
 - acyl cyanides 192
 - proteomic drug research lead compounds 187–203
 - SyproOrange, 2-DE staining methods 35
 - SyproRed, 2-DE staining methods 35
 - SyproRuby, 2-DE staining methods 35
 - system-oriented proteomics 138
 - systematic methodical platform (SMP), HBPP2 12
 - systemic lupus erythematosus (SLE), autoimmune disease 146, 202
- t**
- t*-test
 - DIGE data statistical analysis 50–51
 - paired 52
 - TAP *see* trypsinogen-activating peptide target identification
 - drug discovery process 125
 - materials and methods 190–193
 - SMART 187–203
 - target market, identification 323
 - target validation, tissue microarrays 149–150
 - tasks of administration, proteomics networks 4–6

- tau gene, knock out mice 263–264
tau protein 263–266
– alternative splicing 263
– hyperphosphorylation 264
– increased in Alzheimer’s disease
cerebrospinal fluid 264–265
“Taylor cone”, electrospray ionization 61
TCEP, reducing DIGE agent 44
teriparatide, peptide-based pharmaceutical
117
tetrameric holoenzyme, PKA 161
therapeutic peptide, insulin 113
therapeutic target, anti-inflammatory therapy
218–219
thermodynamic characterization, drug–
therapeutic target interactions 163
thionyl chloride method, acyl chlorides
synthesis 192
TIGRFAMs, protein database 22
time-of-flight *see* TOF
tissue microarrays
– schematic representation 144
– technology 149–150
tissues, morphologically intact 173–182
TMA *see* tissue microarrays
TOF 57, 63
TOF/TOF 63
– schematic representation 64
tonic water, quinine 165
tools
– bioinformatic 20
– development 321
– protein analysis 21–23
– screening 167–169
top-down identification, endogenous
peptides 123–124
top-down proteomics 90
– MD-LC 98–99
topologically organized systems, analysis
176
toponome
– language metaphor 174–176
– molecular networks 180
– multiepitope ligand kartographie (MELK)
180
– profiling 10
– subcellular fingerprint 178
toponomics, HBPP2 12
topotecan
– drug resistance 243
– molecular structure 244
toxic agents, dilated cardiomyopathy (DCM)
contributory factors 300
transcriptome profiling 10
transcriptomics
– minimum information about a microarray
experiment (MIAME) guidelines 25
– renal cell carcinoma (RCC) biomarkers
229
transfected HEK 293 cells 270
transforming growth factor β 1, possible
Alzheimer’s disease biomarkers 267
transgelin, DIGE molecular markers 47
transplantation
– cardiac 307
– heart 306
tris-(carboxyethyl) phosphine hydrochloride
see TCEP
trk-receptors, ligand activation 39–43
TrkA/TrkB 33, 39
– SY5Y cell lysate 40
– SY5Y DIGE 42–43
tropomyosin, differential abundance in
mitoxantrone resistant MCF-7 cells 252
trypsin, digestion 102
trypsinogen-activating peptide (TAP),
pancreatitis biomarker 119
TSH-releasing factor (TRH), discovery 115
tubulin chains, brain proteins 284
tumor biopsies, analysis 226
tumor profiling strategy, random forest
clustering 230
tumor-specific autoantigens, identification
226
tyrosine kinases 150
– noreceptor 189
– pp60c-src 213
– signalling 150
– *see also* TrkA/TrkB
- u**
ubiquitin carboxyl-terminal hydrolase
(UCH), enzyme 301–302
ubiquitination, protein 302
UCH *see* ubiquitin carboxyl-terminal
hydrolase
unbiased proteomics 138
underrepresented protein classes, 2-D gels
294
UniClone sets, German Human Brain
Proteome Project 11
UniParc, archive 21
UniProt, protein analysis tools 21–22
universal gas constant 164
Universal Protein Resource *see* UniProt
urinary proteome, disease-related
information 227
urine, solid phase extraction (SPE) 100

v

- vascular dementia, discrimination from Alzheimer's disease 266
- vasopressin, discovery 115
- vessel proteomics 307–312
- vessels, atherosclerotic 307
- vimentin, DIGE molecular markers 47
- viral infections, dilated cardiomyopathy (DCM) contributory factors 300
- visualization, phosphoprotein 209
- von Hippel Lindau (VHL) gene, renal cell carcinoma (RCC) 224

w

- western blot analysis, heterogeneous annexin IV expression 234
- wild type mice, phosphoproteome differences to knock out mice 218–219
- Winnacker, Ernst-Ludwig 4
- wound healing, protein disulfide isomerase (PDI) 214

x

- xMap technology, microsphere-based 271
- XML implementation, microarray gene expression (MAGE) 25
- XML-MI, protein–protein interaction data format 27

y

- yeast cells, ¹⁵N labeling 70

z

- zinc imidazole, 2-DE staining methods 35